Calithera Biosciences, Inc. (CALA)
0.0002
0.00 (0.00%)
USD |
OTCM |
Feb 19, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.001M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -66.67% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 100.00% |
Profile
| Calithera Biosciences, Inc. is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA. |
| URL | http://www.calithera.com |
| Investor Relations URL | http://ir.calithera.com/phoenix.zhtml?c=253557&p=irol-irhome |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 30, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Calithera Biosciences, Inc. is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA. |
| URL | http://www.calithera.com |
| Investor Relations URL | http://ir.calithera.com/phoenix.zhtml?c=253557&p=irol-irhome |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | Mar. 30, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |